Gossamer Bio, Inc.
GOSS evidence brief
What we can confirm
- BioSniper Score:
- 5.5 / 10
- Market Cap:
- $87.9M
- Lead Asset:
- seralutinib (Phase 3)
What it means
What to watch
Prepared research question
What matters most for GOSS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GOSS
Gossamer Bio, Inc. (GOSS) is a clinical-stage biopharmaceutical company focused on developing and commercializing seralutinib, an inhaled small-molecule inhibitor of PDGFR, CSF1R, and c-KIT, for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Key risk: Single-asset concentration
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 3 clinical trials for Gossamer Bio, Inc..
Gossamer Bio, Inc. (GOSS) is a clinical-stage biopharmaceutical company focused on developing and commercializing seralutinib, an inhaled small-molecule inhibitor of PDGFR, CSF1R, and c-KIT, for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
- Gossamer Bio submitted a New Drug Application (NDA) to the U.S. FDA for seralutinib for the treatment of pulmonary arterial hypertension in September 2026 [news].
- As of June 30, 2026, the company reported cash & equivalents of $41.1M, total revenue of $9.2M, net income of $16.9M, and shareholders' equity of -$94.0M [sec].
- In August 2026, Gossamer Bio secured up to $250 million in structured private placement financing, with $150 million committed and an additional $100 million contingent on FDA approval of seralutinib [news].
- Seralutinib is in Phase 3 development for PAH and has Orphan Drug designation; the company has a joint development partnership with Chiesi for global development and commercialization [pipeline].
- The Phase 2 TORREY trial showed a statistically significant reduction in pulmonary vascular resistance (PVR) with seralutinib compared to placebo (p=0.03) [catalyst].
What works
- Seralutinib has completed a Phase 2 trial (TORREY) with statistically significant improvement in PVR (p=0.03) and an NDA has been submitted to the FDA, indicating progress toward potential approval [catalyst][news].
- The company secured up to $250 million in private placement financing, with $150 million committed, providing capital to fund seralutinib through potential FDA approval [news].
- Gossamer Bio has a partnership with Chiesi for joint development and commercialization, leveraging Chiesi's global reach outside the US [pipeline].
What to weigh
- Gossamer Bio has negative shareholders' equity of -$94.0M as of June 30, 2026, indicating accumulated losses exceed assets [sec].
- The company is a single-asset biopharma focused entirely on seralutinib, making it highly dependent on the success of this one drug [news].
- The competitive landscape for PAH includes established therapies (PDE5 inhibitors, ERAs, prostanoids) and newer entrants like sotatercept, posing market entry challenges [pipeline].
From the filings
Quoted directly from source documents.
NDA submission for seralutinib
“submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in September 2026 for seralutinib for the treatme”
News · September 23, 2026
Phase 2 TORREY trial result
“The least squares mean difference between the seralutinib and placebo groups for change in PVR was -96·1 dyne·s/cm 5 (95% CI -183·5 to -8·8; p=0·03).”
Catalysts · July 31, 2024
Catalyst timeline
- 2024-07-31 · Trial_Readout: Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trial. — The Phase 2 TORREY trial showed a statistically significant reduction in PVR with seralutinib vs placebo (p=0.03), supporting the NDA submission.
- 2024-09-03 · Phase3_Start: An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Seralutinib Orally Inhaled for the Treatment of Pulmonary Arterial Hypertension (PAH) — This open-label extension study is evaluating long-term safety and efficacy of seralutinib in PAH patients.
Risks & what to watch (4)›
Key risks
- Single-asset concentration — Gossamer Bio's entire pipeline is focused on seralutinib; failure of the drug would severely impact the company [news].
- Negative shareholders' equity — Shareholders' equity of -$94.0M as of June 30, 2026 indicates the company is technically insolvent on a net worth basis [sec].
- Competitive PAH market — Seralutinib faces competition from established PDE5 inhibitors, ERAs, prostanoids, and newer agents like sotatercept [pipeline].
- Regulatory uncertainty — The NDA for seralutinib is under FDA review; outcomes are uncertain and could delay or deny approval [news].
What to watch
- FDA acceptance and review timeline for the seralutinib NDA submitted in September 2026 [news].
- Potential FDA approval decision and any post-approval conditions or label restrictions [news].
- Execution of the private placement financing milestones, especially the $100 million tranche contingent on FDA approval [news].
- Any updates from the Phase 3 PROSERA study and long-term extension study (Phase 3) for seralutinib [news][catalyst].
Sources: Catalysts · News · Pipeline · Generated October 11, 2026 · How we verify sources →
Run Gossamer Bio, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Gossamer Bio, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
Net income $17M
Lead: Phase 3
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Short Interest
as of Apr 30, 2026- % of float
- 18.2%
- Days to cover
- 3.6
- Shares short
- 40,196,107
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
GOSS short interestGovernance
Frequently asked questions
What is the AI investment thesis for Gossamer Bio, Inc.?
Gossamer Bio, Inc. (GOSS) is a clinical-stage biopharmaceutical company focused on developing and commercializing seralutinib, an inhaled small-molecule inhibitor of PDGFR, CSF1R, and c-KIT, for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
What is Gossamer Bio, Inc.'s lead drug candidate?
Gossamer Bio, Inc.'s most advanced tracked candidate is seralutinib (Phase 3) for Pulmonary Arterial Hypertension.
Who is the CEO of Gossamer Bio, Inc.?
Mr. Faheem Hasnain is the chief executive officer of Gossamer Bio, Inc. (GOSS).
Where is Gossamer Bio, Inc. headquartered?
Gossamer Bio, Inc. (GOSS) is headquartered in San Diego, CA, United States.
What therapeutic areas does Gossamer Bio, Inc. focus on?
Gossamer Bio, Inc. develops therapies across Oncology, Cardiovascular, Respiratory.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.